Theracryf Plc

DB:8EV Stock Report

Market Cap: €2.7m

Theracryf Future Growth

Future criteria checks 0/6

Theracryf is forecast to grow earnings at 37.3% per annum. EPS is expected to grow by 53.6% per annum.

Key information

37.3%

Earnings growth rate

53.6%

EPS growth rate

Biotechs earnings growth41.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated28 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8EV - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026N/A-2N/A-21
3/31/2025N/A-2-2-22
9/30/2024N/A-3-3-3N/A
6/30/20240-3-3-3N/A
3/31/20240-3-3-3N/A
12/31/20231-3-3-3N/A
9/30/20231-3-4-4N/A
6/30/20231-4-4-4N/A
3/31/20230-4-4-4N/A
12/31/20220-4-4-4N/A
9/30/2022N/A-3-3-3N/A
6/30/2022N/A-3-3-3N/A
3/31/2022N/A-3-3-3N/A
12/31/2021N/A-3-3-3N/A
9/30/2021N/A-2-3-3N/A
6/30/20210-3-3-3N/A
3/31/20210-3-3-3N/A
12/31/20200-3-3-3N/A
9/30/20200-3-3-3N/A
6/30/20200-3-3-3N/A
3/31/2020N/A-3-3-3N/A
12/31/2019N/A-3-3-3N/A
9/30/2019N/A-2-2-2N/A
6/30/2019N/A-3-2-2N/A
3/31/2019N/A-3-2-2N/A
12/31/2018N/A-3-2-2N/A
9/30/2018N/A-3-2-2N/A
6/30/2018N/A-3N/A-2N/A
3/31/2018N/A-3N/A-2N/A
12/31/2017N/A-3N/A-3N/A
9/30/2017N/A-3N/A-3N/A
6/30/2017N/A-3N/A-3N/A
3/31/2017N/A-3N/A-3N/A
12/31/2016N/A-3N/A-3N/A
9/30/2016N/A-4N/A-3N/A
6/30/2016N/A-3N/A-2N/A
3/31/2016N/A-3N/A-2N/A
12/31/2015N/A-3N/A-1N/A
9/30/2015N/A-2N/A-1N/A
6/30/2015N/A-2N/A-1N/A
3/31/2015N/A-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8EV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8EV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8EV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8EV's revenue is forecast to grow faster than the German market.

High Growth Revenue: 8EV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8EV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:49
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theracryf Plc is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colin SmithCapital Access Group
Adam McCarterCavendish